NEW DELHI: Biologic therapies are revolutionising severe asthma management, showcasing potential for remission, but cost and equitable access are the major barriers, according to a report on Tuesday.
ALK (ALKB:DC / OMX: ALK B) today announced that its European regulatory filing for ACARIZAX® (house dust mite sublingual allergy immunotherapy tablet) in young children aged five to 11 has been ...